A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.
Dutasteride and oral minoxidil are not effectively stopping hair loss for the user, despite trying various treatments including ketoconazole shampoo. Suggestions include increasing dosages, considering alternative treatments, and consulting a doctor.
The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
Ketoconazole shampoo may help with early-stage hair loss by stopping hair regression and promoting new hair growth, though its effectiveness as a DHT blocker is debated. Users report varying results, with some experiencing dryness and others seeing improvement when used 2-3 times a week.
A sugar gel called 2-deoxy-D-ribose (2dDR) shows potential for promoting hair regrowth by increasing blood supply to hair follicles, similar to Minoxidil, but its effectiveness in humans is unproven. It may benefit those who don't tolerate Minoxidil, but it is not a replacement for treatments like Finasteride or RU58841.
The user shares a positive experience with Dutasteride for hair loss, noting increased hair density and minimal side effects after switching from Finasteride. They prefer oral Dutasteride and avoid Minoxidil due to its inconvenience and potential risks.
User discusses hair loss treatment progress using Dutasteride for 2 years, RU58841 for 5 months, and oral Minoxidil for 1 year. Some users share side effects and experiences with these treatments.
The user has been using oral Minoxidil, finasteride, dermastamping, and Ketoconazole for hair regrowth with positive results and no side effects. They plan to switch to dutasteride but face challenges obtaining it legally in Germany.
The conversation is about someone who has been using finasteride and minoxidil for over three years without satisfactory results for hair thinning. They have started using dutasteride and added RU58841 seven months ago but have not seen improvements yet.
The user has been using dutasteride, minoxidil, and RU58841 for two years but continues to experience excessive hair shedding, despite also taking various supplements and trying other treatments like red light therapy. They are seeking advice and sharing experiences with others facing similar hair loss challenges.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
The user shared progress on hair regrowth using 5% topical minoxidil, 2% keto shampoo, oral finasteride, and recently switched to daily dutasteride. They reported positive results without significant side effects and are hopeful for further improvement.
Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.
A 40-year-old shared progress pictures showing results after 3.5 months of using dutasteride for hair loss. The conversation likely discusses this specific treatment and its effects on hair regrowth.
The user has been on dutasteride and oral minoxidil for a year with no progress and is considering increasing the dutasteride dose or adding RU58841. Other users suggest consulting a doctor, trying derma needling with topical minoxidil, and note that hair loss treatments can have varying effectiveness.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.
The user achieved significant hair regrowth using only dutasteride, noticing results after 8-9 months despite initial shedding. They did not use minoxidil due to inconvenience but still experienced permanent hair growth.
Increasing the dutasteride dose to 2.5 mg may significantly reduce DHT and promote hair regrowth, with similar side effects to lower doses. Some users combine dutasteride with minoxidil and finasteride for better results, but there are concerns about long-term effectiveness and availability.
A user shared their two-month progress using dutasteride, minoxidil, ketoconazole shampoo, and tretinoin cream for hair loss, reporting no side effects and increased sex drive. Other users discussed their experiences with similar treatments, including finasteride and oral minoxidil, and debated the effectiveness of microneedling.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.